-
Golf star Rahm quitting LIV tour over 'unacceptable' terms
-
Trump plans to turn Florida golf course into presidential retreat
-
Thousands march fearing return of a Bolsonaro presidency in Brazil
-
WHO says cannot conduct full risk assessment on Russia plague reports
-
French PM denies police ordered to confront student protesters
-
After botched execution, US woman is awake and shackled to bed
-
Rubio touts US power, calls on Europe to emerge from 'slumber'
-
New Zealand fly-half Mo'unga ruled out of Australia Tests
-
Trump says 'we don't think' Russian plague is bio-weapon
-
Protests in major Turkish city after mayor defects to Erdogan party
-
Five children among 26 killed in Ukraine after Russian strikes
-
Climate change strips island's title of largest penguin colony: study
-
Man City should 'accept' punishment for rule breaches, says Lineker
-
Rubio says West must choose between national power or decline
-
US woman who survived botched execution is awake and speaking
-
Russia's plague scare: What we know
-
From 1800s to modern pharma: a Nobel-winning chemistry quest
-
French luxury giant to fund redevelopment of two Paris streets: city hall
-
Southampton boss Eckert given suspended ban over 'Spygate'
-
Trump wants to turn Florida golf course into presidential retreat
-
Russia warns of 'false' information as second plague case reported
-
Mayor of Turkish opposition stronghold defects to Erdogan party
-
IEA ready to release more oil reserves if necessary
-
Children among heavy casualties in Ukraine after Russian strikes
-
HSBC 'consults' over UK unit job cuts amid AI adoption
-
Court orders German ex-spy chief kept in jail after spying, treason arrest
-
UK court quashes five ex-traders' Libor rate rigging convictions
-
Guinea caps bottled water prices after sachets banned
-
XM Receives “Global Customer Experience Leader Award 2026” at the TrustFinance Performance Awards
-
Spared, married, hanged: the last weeks of Iranian protester Alireza Sepahi
-
Stocks slide as oil climbs on Mideast flareup
-
Nobel physics winner's pride at pioneering AI role
-
Heavy casualties in Ukraine after Russian strikes
-
IMF preparing El Nino assistance, concerned about AI bubble burst: chief to AFP
-
French wine harvest set to hit historic low
-
West must embrace 'national power' or face decline: Rubio
-
Kyiv 'cannot agree' to EU membership limiting food exports: minister
-
Shell refining margins reach record highs as wars hit supply
-
Arteta targets more Arsenal glory after signing new deal until 2030
-
Former Spain, Barca winger Pedro retires from football
-
Russell hit with Singapore grid penalty for taking new power unit
-
Arteta signs new Arsenal deal until 2030
-
Spotify expands audiobooks to more than 180 markets
-
Stocks decline as oil climbs on Mideast flareup
-
French-Japanese duo wins chemistry Nobel for solving molecular 'mystery'
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
X.AbuJaber--SF-PST